Antibody General Information
Name DXP-593    AB6784
Alias BGB-DXP593
Type Antibody [Ab]
Protein/Region S; RBD
Origin B-cells (SARS-CoV2 Human Patient/Vaccinee)
Binds To SARS-CoV-1
SARS-CoV-2_WT
Pangolin-GD (Source
Neutralizing Vs SARS-CoV-2_WT+D614G
Pangolin-GD (Source)
Not Neutralizing Vs SARS-CoV-1
SARS-CoV-2_WT+XBB
SARS-CoV-2_Omicron(BA.1)
SARS-CoV-2_Omicron(BA.2)
SARS-CoV-2_Omicron(BA.3)
SARS-CoV-2_Omicron(BA.4)
SARS-CoV-2_Omicron(BA.5)
SARS-CoV-2_Omicron(BQ.1.1)
RaTG13 (Source)
Binding Affinity and Neutralization
This table lists binding affinity and neutralization data of DXP-593.
The binding affinity constant (KD, in nM units) determined by SPR and BLI can be used to evaluate the binding affinity of antibodies. Specifically, for the measured value x, x < 10 indicates a higher binding affinity, 10 ≤ x < 1000 indicates a moderate binding affinity, x ≥ 1000 indicates a lower binding affinity or even no binding.
The IC50, measured in ug/ml units using virus neutralization and ELISA assays, can be used to assess the neutralization activity of antibodies. Specifically, for the measured value x, x < 1 indicates a stronger neutralization activity, 1 ≤ x < 10 indicates a weak neutralization activity, x ≥ 10 indicates little or no neutralization activity.
Gene and Sequence
Heavy Chain Gene V Gene IGHV3-23 (Human)
J Gene IGHJ4 (Human)
Light Chain Gene V Gene IGKV2-28 (Human)
J Gene IGKJ5 (Human)
VH or VHH EVQLLESGGGVVQPGGSLRLSCAASGFAFTTYAMNWVRQAPGRGLEWVSAISDGGGSAYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKTRGRGLYDYVWGSKDYWGQGTLVTVSS
VL DIVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPGTFGQGTRLEIK
CDRH3 AKTRGRGLYDYVWGSKDY
CDRL3 MQALQTPGT
Reference
Ref 1 Yunlong Cao et al., 2022 (https://www.biorxiv.org/content/10.1101/2022.09.15.507787v2)
Ref 2 Yunlong Cao et al. 2022 (https://www.nature.com/articles/s41586-022-04980-y#Sec4)
Data Update
Date Added Nov 7, 2023
Date Updated Nov 7, 2023
Update Description Nov 7, 2023. First Added